Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome

CAPP2 Investigators, John Burn, D Timothy Bishop, Jukka-Pekka Mecklin, Finlay Macrae, Gabriela Möslein, Sylviane Olschwang, Marie-Luise Bisgaard, Raj Ramesar, Diana Eccles, Eamonn R Maher, Lucio Bertario, Heikki J Jarvinen, Annika Lindblom, D Gareth Evans, Jan Lubinski, Patrick J Morrison, Judy W C Ho, Hans F A Vasen, Lucy SideHuw J W Thomas, Rodney J Scott, Malcolm Dunlop, Gail Barker, Faye Elliott, Jeremy R Jass, Ricardo Fodde, Henry T Lynch, John C Mathers

Research output: Contribution to journalArticlepeer-review


Observational and epidemiologic data indicate that the use of aspirin reduces the risk of colorectal neoplasia; however, the effects of aspirin in the Lynch syndrome (hereditary nonpolyposis colon cancer) are not known. Resistant starch has been associated with an antineoplastic effect on the colon.
Original languageEnglish
Pages (from-to)2567-78
Number of pages12
JournalNew England Journal of Medicine
Issue number24
Publication statusPublished - 11 Dec 2008


  • Adenoma
  • Adult
  • Aged
  • Aspirin
  • Carcinoma
  • Colorectal Neoplasms
  • Colorectal Neoplasms, Hereditary Nonpolyposis
  • DNA Mismatch Repair
  • Drug Therapy, Combination
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Risk
  • Starch
  • Treatment Failure


Dive into the research topics of 'Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome'. Together they form a unique fingerprint.

Cite this